Effects of patient factors on inpatient mortality after complex liver, pancreatic and gastric resections.

BACKGROUND: There is mixed evidence that patients who receive care in hospitals with a low case volume for complex gastrointestinal and hepatobiliary operations have an increased risk of inpatient death. METHODS: A retrospective cohort study was performed of patients who had complex gastrointestinal and hepatobiliary operations in the Healthcare Cost and Utilization Project 2012 National Inpatient Sample. Multivariable weighted hierarchical generalized linear models were used to test the relationship between hospital case volume and probability of inpatient death, with detailed adjustments for the concurrent effects of differences in associated patient co-morbidities. RESULTS: A total of 8260 pancreaticoduodenectomies, 2750 major hepatectomies and 3250 total gastrectomies were identified. Inpatient death occurred in 3·6 per cent of patients after pancreaticoduodenectomy, 4·9 per cent after major hepatectomy and 4·6 per cent after total gastrectomy. Mean hospital case volume was 50·6 (median 40) for pancreaticoduodenectomy, 23·6 (median 15) for major hepatectomy, 15·1 (median 10) for total gastrectomy and 70·2 (median 50) for any of the three operations. Hospital case volume was not a statistically significant predictor of mortality after any operation (all P ≥ 0·188). Patient characteristics including age and co-morbidity were highly significant predictors of mortality (P < 0·001). No significant improvements in model performance were obtained by adding hospital case volume to any model that already included adjustments for patient-level differences in age and co-morbid disease, for any functional format (P ≥ 0·146 for all C statistic differences from baseline). CONCLUSION: Patient co-morbidity, not hospital case volume, was associated with significant differences in inpatient mortality following complex gastric, pancreatic and hepatobiliary resections.

Cancer patient-reported outcomes assessment using wireless touch screen tablet computers.

PURPOSE: To assess the feasibility of collecting patient-reported outcomes data with wireless touch screen tablet computers in the adult oncology palliative care setting. METHODS: Patients were provided with tablet computers during scheduled clinic visits and answered online queries about their experience over the past week in the health domains of anxiety, depression, fatigue, pain interference, physical function, instrumental social support, sleep impairment, diarrhea, constipation, nausea, vomiting, anorexia, dyspnea, neuropathy, and spiritual values. RESULTS: Content analysis of patient interviews indicates that wireless touch screen tablet computers are a feasible approach for collecting patient-reported outcome measures by palliative care cancer patients presenting in clinic. Most patients indicated that the questionnaire was easy to answer. However, all but one patient requested some form of assistance, and many reported difficulties attributable to a lack of familiarity with the device, interpretation of certain questions, and wireless connectivity-related issues. CONCLUSIONS: This feasibility study demonstrates that tablet computers have the potential to efficiently and reliably collect patient-reported health status measures among palliative care cancer patients presenting in clinics. The use of these devices may lead to substantial improvements by making patient-reported outcomes available for clinical decision-making.

Regional variability in symptom-based MELD exceptions: a response to organ shortage?

MELD (model for end-stage liver disease) exception awards affect the liver allocation process. Award rates of specific nonhepatocellular carcinoma exceptions, termed symptom-based exceptions (SBE), differ across UNOS regions. We aimed to characterize the regional variability in SBE awards and examine predictive factors for receiving a SBE in the MELD era. The OPTN liver transplant and waiting list dataset was analyzed for waiting list registrants during the MELD allocation on February 27, 2002, until November 22, 2006. Competing risks proportional hazards regression analysis was used to examine predictors for receiving a SBE in 39 169 registrants. The hazard ratios for receiving a SBE differed significantly across regions when adjusted for multiple variables including age, gender, ethnicity, physiologic MELD score, blood group, functional status, etiology of liver disease, insurer and education level. Utilization of SBE is highly significantly variable across UNOS regions, and does not correlate with organ availability as estimated by the regional mean physiologic MELD score at transplantation. Patients with Medicaid as their primary payer have a lower likelihood of receiving a SBE award, while patients with cryptogenic/NASH cirrhosis or cholestatic liver disease have a higher likelihood of receiving a SBE. Reasons for these regional and demographic disparities deserve further investigation.

A cost comparison of two strategies for treating stage IB2 cervical cancer.

Patients with stage IB2 cervical cancer at our institution are treated primarily with definitive chemoradiation, or chemoradiation followed by adjuvant hysterectomy. We sought to compare the cost differences associated with these two strategies. We identified all patients with stage IB2 cervical cancer who received their entire treatment regimen at our institution between 1995 and 2004. All patients received a combination of chemotherapy, external beam radiation, and one brachytherapy procedure, followed by either a second brachytherapy procedure or a simple hysterectomy. We retrieved cost data associated with hospitalization for the completion of respective treatment, including pharmacy, laboratory and pathology, radiation, and operating room services, as well as the costs of supplies and room and board. We identified 46 patients with stage IB2 cervical cancer, 23 who received a second brachytherapy procedure and 23 who underwent simple hysterectomy. Patients displayed similar demographics and similar disease characteristics including initial tumor diameter and histology. The cost of care for adjuvant hysterectomy group was greater ($8,316.70 vs 5,508.70, P < 0.0001). Specific differences included higher operating room costs ($1520 vs 414, P < 0.0001), pharmacy costs ($675 vs 342, P < 0.0001), and laboratory/pathology costs ($597 vs 89, P < 0.0001). We conclude that definitive chemoradiation appears to be associated with lower costs for management of stage IB2 cervical cancer when compared to simple adjuvant hysterectomy.

Survival after adult liver transplantation does not correlate with transplant center case volume in the MELD era.

It has been demonstrated that low-volume orthotopic liver transplant centers have poorer outcomes compared to high-volume centers. In light of the recent significant changes in liver transplantation, we performed an analysis of transplant center procedure volume and mortality with data from the Model for End-stage Liver Disease (MELD) era. We analyzed 9909 adult liver transplants performed in the United States since the beginning of the MELD allocation system. Transplant centers were categorized by volume of transplants performed per year. Multivariate survival models were constructed with raw survival as the primary endpoint for both high- and low-volume centers. Thirty percent of centers were categorized as low volume (< or =20 liver transplants per year) and 8.2% of all transplants were performed at low-volume centers. The unadjusted raw mortality rate at 1-year post-transplant at high-volume centers (9.5%, 95% CI 9.4-9.5) was significantly lower than the rate at low-volume centers (10.9%, 95% CI 10.4-11.4), p < 0.001. However, after adjusting for disease severity and multiple donor and recipient factors, transplant center volume was no longer a significant predictor of post-transplant survival (HR 0.99, 95% CI 0.99-1.00, p = 0.22). We conclude that transplant center case volume is no longer a significant predictor of post-transplant survival in the MELD era and factors which are currently unaccounted for in present survival models should be investigated.

Adding value to clinical data by linkage to a public death registry.

We describe the methodology and impact of merging detailed statewide mortality data into the master patient index tables of the clinical data repository (CDR) of the University of Virginia Health System (UVAHS). We employ three broadly inclusive linkage passes (designed to result in large numbers of false positives) to match the patients in the CDR to those in the statewide files using the following criteria: a) Social Security Number; b) Patient Last Name and Birth Date; c) Patient Last Name and Patient First Name. The results from these initial matches are refined by calculation and assignment of a total score comprised of partial scores depending on the quality of matching between the various identifiers. In order to validate our scoring algorithm, we used those patients known to have died at UVAHS over the eight year period as an internal control. We conclude that we are able to update our CDR with 97% of the deaths from the state source using this scheme. We illustrate the potential of the resulting system to assist caregivers in identification of at-risk patient groups by description of those patients in the CDR who were found to have committed suicide. We suggest that our approach represents an efficient and inexpensive way to enrich hospital data with important outcomes information.

Comparison of the performance of two comorbidity measures, with and without information from prior hospitalizations.

OBJECTIVES: This study compares the performance of two comorbidity risk adjustment methods (the Deyo et al adaptation of the Charlson index and the Elixhauser et al method) in five groups of California hospital patients with common reasons for hospitalization, and assesses the contribution to model performance made by information drawn from prior hospital admissions. METHODS: California hospital discharge abstract data for the calendar years 1994 through 1997 were used to create a longitudinal data set for patients in the five disease groups. Eleven logistic regression models were estimated to predict the risk of in-hospital death for patients in each group, with both comorbidity risk adjustment methods applied to patient information available from only the index hospitalization, and to information available from both the index and prior hospitalizations. RESULTS: For every comparison made, the level of statistical performance (area under the receiver operating characteristics curve) demonstrated by models using the Elixhauser et al method was superior to that of models using the Deyo et al adaptation method. Although most patients have information available from prior hospital admissions, this additional information yields only small improvements in the performance of models using either comorbidity risk adjustment method. CONCLUSIONS: Better discrimination is achieved with the Elixhauser et al method using only information from the index hospitalization than is achieved with the Deyo et al adaptation using information from all identified hospital admissions. Both comorbidity risk adjustment methods achieve their best performance when information from the index hospitalization and prior admissions is separated into independent indicators of comorbid illness.

The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients.

An association may exist between Crohn's disease (CD) and lymphoid/myeloid malignancies. We aimed to evaluate the 2-year cumulative incidence rate of lymphoid/myeloid malignancy among hospitalized CD patients. This is a retrospective cohort study using hospital discharge data from California and Virginia. Cohorts were defined by the presence or absence of a CD diagnosis in all patients discharged during a single calendar year (Year-2). The presence or absence of lymphoid/myeloid malignancy was determined for all hospitalizations during a 4-year period (Year-1 to Year-4) for each member of both cohorts. To obtain a 2-year cumulative incidence rate, patients with lymphoid/myeloid malignancy prior to or at the time of their first admission in Year-2 were excluded. Patients were followed for 8 quarters after this admission for the incidence of lymphoid/myeloid malignancy. Cumulative incidence rates and odds ratios were calculated. The crude 2-year incidence rate of lymphoid/myeloid malignancy among hospitalized CD patients was 3.87/1.000 CD patients (21/5,426; 95% CI = 2.40-5.92). The odds ratio adjusted for age, gender, and race was 2.04 (95% CI = 1.33-3.14, p < 0.001). The 2-year cumulative incidence of lymphoid/myeloid malignancies among hospitalized CD patients is greater than that seen in hospitalized patients without CD. This finding supports the need for further prospective population-based studies.

Comparison of carotid endarterectomy outcomes from randomized controlled trials and Medicare administrative databases.

OBJECTIVE: To compare the characteristics and outcomes demonstrated for participants in randomized controlled trials of carotid endarterectomy with those of the Medicare patient population who received the procedure in 1989. DESIGN: Historical cohort study using Medicare claims data. SETTING: Medicare beneficiary population aged 65 years and older. PATIENTS: Medicare patients 65 years and older who received carotid endarterectomy during 1989. MAIN OUTCOME MEASURES: Perioperative mortality rate and occurrence of transient ischemic attack, stroke, and death within 2 years of surgery. RESULTS: The risk for death within 2 years of the procedure was substantially higher among Medicare patients who received surgery in hospitals with perioperative mortality rates greater than rates demonstrated in the trials (odds ratio, 1.36; 95% confidence interval, 1.29-1.44) and among those with comorbidity that exceeded trial participation criteria (odds ratio, 1.72; 95% confidence interval, 1.64-1.84). CONCLUSIONS: Although carotid endarterectomy trials demonstrate the efficacy of the procedure, this evidence only applies to patients and hospitals with characteristics comparable to those of the trial participants. The importance of this consideration is demonstrated by the substantially higher odds of death experienced among Medicare patients receiving the procedure who had a level of comorbidity that exceeded that of the trial participants or who received their surgery in a hospital with a perioperative mortality rate that exceeded the experience of the hospitals in the trials.

The ideal physician: implications for contemporary hospital marketing.

A questionnaire asking individuals to identify freely the characteristics most descriptive of physicians who are closest to their ideal was mailed to a systematically derived cluster sample in a medium-size metropolitan area. Respondents clearly valued psychosocial and interpersonal characteristics such as communicating and caring much more than technical medical skills.